Dylan Martini, MD, Dana-Farber Cancer Institute presents Outcomes in PD-1/PD-L1 inh. responders who discontinued therapy for immune-related adverse events: Analysis of nine patients with metastatic renal cell carcinoma at the 2016 annual International Kidney Cancer Symposium.
Outcomes in PD-1/PD-L1 inh. responders who discontinued therapy for immune-related adverse events: Analysis of nine patients with metastatic renal cell carcinoma
